Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

NCT03866382 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03866382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03866382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
May 13, 2019
Completion date
February 28, 2027
Enrollment
314 (estimated)
Sites
581

Conditions

As the registry lists them; a condition with its own page is linked.

bladder adenocarcinoma, bladder clear cell adenocarcinoma, bladder mixed adenocarcinoma, bladder neuroendocrine carcinoma, bladder small cell neuroendocrine carcinoma, bladder squamous cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma, invasive bladder giant cell urothelial carcinoma, invasive bladder lymphoepithelioma-like carcinoma, invasive bladder nested urothelial carcinoma, invasive bladder plasmacytoid urothelial carcinoma, invasive bladder sarcomatoid urothelial carcinoma, invasive bladder urothelial carcinoma, kidney medullary carcinoma, large cell neuroendocrine carcinoma, malignant testicular leydig cell tumor, malignant testicular sertoli cell tumor, metastatic bladder carcinoma, metastatic bladder clear cell (glycogen-rich) urothelial carcinoma, metastatic bladder giant cell urothelial carcinoma, metastatic bladder large cell neuroendocrine carcinoma, metastatic bladder lipid-rich urothelial carcinoma, metastatic bladder micropapillary urothelial carcinoma, metastatic bladder plasmacytoid urothelial carcinoma, metastatic bladder sarcomatoid urothelial carcinoma, metastatic bladder small cell neuroendocrine carcinoma, metastatic bladder squamous cell carcinoma, metastatic chromophobe renal cell carcinoma, metastatic kidney medullary carcinoma, metastatic malignant genitourinary system neoplasm, metastatic papillary renal cell carcinoma, metastatic penile carcinoma, metastatic prostate small cell neuroendocrine carcinoma, metastatic sarcomatoid renal cell carcinoma, metastatic urethral carcinoma, papillary renal cell carcinoma, sarcomatoid renal cell carcinoma, stage iv bladder cancer ajcc v8, stage iv penile cancer ajcc v8, stage iv renal cell cancer ajcc v8, stage iv urethral cancer ajcc v8, stage ivb prostate cancer ajcc v8, urachal adenocarcinoma, urethral clear cell adenocarcinoma